Cargando…
Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of ran...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800359/ https://www.ncbi.nlm.nih.gov/pubmed/26996569 http://dx.doi.org/10.3349/ymj.2016.57.3.681 |
_version_ | 1782422470708428800 |
---|---|
author | Zhang, Xi-Mei Zhang, Yun-Bo Chi, Mei-Hua |
author_facet | Zhang, Xi-Mei Zhang, Yun-Bo Chi, Mei-Hua |
author_sort | Zhang, Xi-Mei |
collection | PubMed |
description | PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of randomized controlled trials (RCTs). MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane databases up to March 2015 for RCTs. Pooled estimates and 95% confidence intervals (CIs) were calculated by the fixed-and-random-effects model. A total of eleven studies with eleven clinical variables met the inclusion criteria. RESULTS: The meta-analysis showed that fasting plasma glucose (FPG) [weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting serum insulin (FSI) (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005), homeostasis model of assessment for insulin resistance index (HOMA-IR) (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002), diastolic blood pressure (DBP) (WMD, -0.230; 95% CI, -0.441 to -0.019; p=0.033), low-density lipoprotein cholesterol (LDL-C) (WMD, -0.304; 95% CI, -0.461 to -0.148; p=0.000), total cholesterol (TC) (WMD, -0.386; 95% CI, -0.548 to -0.225; p=0.000), and C-reactive protein (CRP) (WMD, -0.510; 95% CI, -0.722 to -0.299; p=0.000) are significant reduced with soy protein supplementation, compared with a placebo control group, in T2D and MS patients. Furthermore, soy protein supplementation for longer duration (≥6 mo) significantly reduced FPG, LDL-C, and CRP, while that for a shorter duration (<6 mo) significantly reduced FSI and HOMA-IR. CONCLUSION: Soy protein supplementation could be beneficial for FPG, FSI, HOMA-IR, DBP, LDL-C, TC, and CRP control in plasma. |
format | Online Article Text |
id | pubmed-4800359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Yonsei University College of Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-48003592016-05-01 Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome Zhang, Xi-Mei Zhang, Yun-Bo Chi, Mei-Hua Yonsei Med J Original Article PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of randomized controlled trials (RCTs). MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane databases up to March 2015 for RCTs. Pooled estimates and 95% confidence intervals (CIs) were calculated by the fixed-and-random-effects model. A total of eleven studies with eleven clinical variables met the inclusion criteria. RESULTS: The meta-analysis showed that fasting plasma glucose (FPG) [weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting serum insulin (FSI) (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005), homeostasis model of assessment for insulin resistance index (HOMA-IR) (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002), diastolic blood pressure (DBP) (WMD, -0.230; 95% CI, -0.441 to -0.019; p=0.033), low-density lipoprotein cholesterol (LDL-C) (WMD, -0.304; 95% CI, -0.461 to -0.148; p=0.000), total cholesterol (TC) (WMD, -0.386; 95% CI, -0.548 to -0.225; p=0.000), and C-reactive protein (CRP) (WMD, -0.510; 95% CI, -0.722 to -0.299; p=0.000) are significant reduced with soy protein supplementation, compared with a placebo control group, in T2D and MS patients. Furthermore, soy protein supplementation for longer duration (≥6 mo) significantly reduced FPG, LDL-C, and CRP, while that for a shorter duration (<6 mo) significantly reduced FSI and HOMA-IR. CONCLUSION: Soy protein supplementation could be beneficial for FPG, FSI, HOMA-IR, DBP, LDL-C, TC, and CRP control in plasma. Yonsei University College of Medicine 2016-05-01 2016-03-15 /pmc/articles/PMC4800359/ /pubmed/26996569 http://dx.doi.org/10.3349/ymj.2016.57.3.681 Text en © Copyright: Yonsei University College of Medicine 2016 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Zhang, Xi-Mei Zhang, Yun-Bo Chi, Mei-Hua Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome |
title | Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome |
title_full | Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome |
title_fullStr | Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome |
title_full_unstemmed | Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome |
title_short | Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome |
title_sort | soy protein supplementation reduces clinical indices in type 2 diabetes and metabolic syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800359/ https://www.ncbi.nlm.nih.gov/pubmed/26996569 http://dx.doi.org/10.3349/ymj.2016.57.3.681 |
work_keys_str_mv | AT zhangximei soyproteinsupplementationreducesclinicalindicesintype2diabetesandmetabolicsyndrome AT zhangyunbo soyproteinsupplementationreducesclinicalindicesintype2diabetesandmetabolicsyndrome AT chimeihua soyproteinsupplementationreducesclinicalindicesintype2diabetesandmetabolicsyndrome |